Medical device company Hemovent GmbH reported on Monday the receipt of the CE marking for its MOBYBOX Runner Controller, to market the product throughout the heart and lung support market in the EU.
The company said the Runner is designed to slingshot clinicians into a new era of mobility and ease of use. The device is designed for Extracorporeal Life Support (ECLS) applications, including Extracorporeal CardioPulmonary Resuscitation (ECPR) to treat patients in cardiac arrest or profound circulatory shock.
Following the Runner EU regulatory approval, the company has created an entirely new solution for the extreme challenges of ECLS deployment in situations with unpredictable and severely restricted emergency environments, said Oliver Marseille, PhD, chief technology officer of Hemovent and a co-founder of CircuLite (Heartware International) prior to co-founding Hemovent.
In 2019, the company receive the CE mark for the MOBYBOX System with the Master Controller and is currently in preparing a post market clinical follow-up trial.
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
American Regent recalls one lot of Papaverine Hydrochloride Injection due to particulate matter
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis